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Alloreactivity is a response of the immune system to indi-
vidual antigenic differences within species. These responses
in general occur following exposure to alloantigens as a
consequence of medical intervention (such as transfusion or
tissue transplantation) or during pregnancy. Responses to
alloantigens form a basis of a broad spectrum of medical
conditions, such as graft rejection, graft versus host disease,
reaction to blood (products), or biopharmaceuticals and fetal
and neonatal diseases (thrombocytopenia, hemolytic anemia,
hemochromatosis, biliary atresia, and glomerulopathy). On
the other hand, normal pregnancies are often accompanied by
strongly tolerogenic responses to fetal alloantigens. Diverse
immunologic components, including T cells, antibodies (B
cells), and NK cells, promote alloreactivity, and this complex-
ity makes the pathogenesis and tolerogenesis of these condi-
tions distinct and unique. This special issue contains seven
manuscripts touching on various aspects of alloreactivity in
medicine.
Blocking CD40-CD40L interaction can induce accep-
tance of cardiac allografts. However, the blockade is less
efficient under inflammatory conditions. In “Glucocorticoid-
induced TNFR-related protein reverses cardiac allograft accep-
tance induced by CD40-CD40L blockade,” Krill et al. demon-
strate that stimulation of GITR (a cell surface molecule
displayed by effector and regulatory T cells) can initiate
cardiac graft rejection irrespective of the presence or absence
of CD40-CD40L blockade, defining thus at least one pos-
sible molecular mechanism of resistance to CD40-CD40L
suppression.The balance between the effector and regulatory
T cells is critical for development of graft-specific immune
responses in general. Franzese et al. review the usefulness of
this balance in predicting or establishing the diagnosis of graft
rejection in “Regulatory T cells in the immunodiagnosis and
outcome of kidney allograft rejection.”
Allogeneic hematopoietic stem cell transplantation is
used for treatment of autoimmune diseases, multiple organ
transplantation, consequences of supralethal irradiation and
advanced malignancies and other serious conditions refrac-
tory to conventional methods. In “New allogeneic hematopoi-
etic cell transplantation method: hematopoietic cell transplan-
tation plus thymus transplantation for intractable diseases,”
Hosaka demonstrates that allogeneic hematopoietic stem
cell transplantation combined with the same donor thymus
transplantation has a superior effect producingmore efficient
T cell function and reduced graft versus host disease.
Redzovic et al., in “Mucins help to avoid alloreactivity
at the maternal fetal interface,” review roles of mucin-1
and tumor associated glycoprotein-72 in regulating immune
responses. Parallels are drawn between the ability of these
molecules to promote tumor growth, invasion, andmetastasis
and to prevent trophoblast invasion. Removing glycoproteins
TAG-72 and Muc 1 from the eutopic implantation site likely
contributes to better control of trophoblast invasion by T cells
and NK cells. This enables tolerance to paternal antigens of
the fetus and normal course and outcome of the pregnancy.
Three manuscripts explore distinct aspects of alloan-
tibody formation. Preformed donor HLA class I-specific
antibodies are a risk factor for rejection of kidney, heart, and
lung grafts, but the role of these antibodies is less clear in liver
transplantation, where rejection rates are lower. Yoshizawa
et al., in “Significance of semiquantitative assessment of pre-
formed donor-specific antibody using luminex single bead assay
2 Clinical and Developmental Immunology
in living related liver transplantation,” describe a quantitative
assay for donor specific antibodies that has a predictive value
for living donor liver transplantation. In “Nuclear antigens
and auto/alloantibody responses: friend or foe in transplant
immunology,” Nakano et al. review current thinking about the
role of nuclear antigens and antibodies specific for nuclear
antigens in initiation and regulation of immune responses
and graft rejection. Finally, transfusion of allogeneic red
blood cells may in some recipients induce alloantibodies.
Tatari-Calderone et al. in “The association of CD81 polymor-
phisms with alloimmunization in sickle cell disease” suggest
that genetic elements in the gene encoding B-cell molecule
CD81 may be predictive markers of alloimmunization.
The huge breadth of the field of alloreactivity-based
medical conditions allows the special issue only to scratch
under the surface of any specific topic. Our hope, however, is
that this issue will help raise awareness of the immunological
basis of these conditions and will foster further efforts to
better understand their pathogenesis. Ultimately, this should
help us design better treatments or prevent the development
of these medical conditions altogether.
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